Cat. No.: HY-100009

Ufenamate

(Synonyms: Flufenamic acid butyl ester; Butyl flufenamate)

Customer Review

Based on 1 Customer Validation

Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2.

For research use only. We do not sell to patients.

Purity: 99.89%
CAS No.: 67330-25-0
Formula: C₁₈H₁₈F₃NO₂
Molecular Weight:337.34

Storage:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ufenamate Chemical Structure

CAS No.: 67330-25-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

COX-2

All COX Isoforms :

All Prostaglandin Receptor Isoforms :

In Vivo

Ufenamat (2 µL/cm², ointment application, single dose) is not suitable for dry skin in rats^[2].
Ufenamate (Ointment application, single dose) has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging mice model and downregulates the expression level of COX-2^[3].
Ufenamat (Ointment application, 6 and 8 weeks) promotes the healing of skull injuries in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

UV-induced acute sunburn model, photoaging model and skin squamous cell carcinoma model in SKH-1 hairless mice^[3]
Dosage:

Ointment application
Administration:

Ointment application; single dose; 30 min
Result:

Inhibited acute swelling and redness caused by UV irradiation and reduced COX-2 expression.
At 12 weeks of irradiation, skin aging was alleviated, the collagen density of the dermis was higher, the expression of Bcl-2 was weakened, and the expression of Bax and Caspase 3 was enhanced.
At 28 weeks of irradiation, the appearance of tumors was delayed.

Animal Model:

Intact and damaged skin of rats^[2]
Dosage:

2µL/cm²
Administration:

Ointment application; single dose
Result:

Applied on the damaged skin, contained in the epidermis was approximately 50% and 25% of that in the intact skin after LP and water, respectively, with the content being 5 times and 10 times higher than in the intact skin.
Permeated UF five times more than LP in the intact skin. Reduced significantly the permeation of UF by both LP and water due to the defatting effect of SC.

Animal Model:

Skull defect mice^[4]
Dosage:

Ointment application
Administration:

Ointment application; 6 weeks and 8 weeks
Result:

Promoted the formation of new bone in the defect area, and the effect was stronger after 8 weeks than at 6 weeks, improving the BV/TV and BMD in the defect area.

Chemical Information

CAS No. 67330-25-0
Appearance Liquid (Density: 1.2230 g/cm³)
Molecular Weight 337.34
Formula C₁₈H₁₈F₃NO₂
Color Colorless to light yellow
SMILES

O=C(OCCCC)C1=CC=CC=C1NC2=CC=CC(C(F)(F)F)=C2
Synonyms

Flufenamic acid butyl ester; Butyl flufenamate
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 44 mg/mL (130.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9644 mL

14.8218 mL

29.6437 mL

5 mM

0.5929 mL

2.9644 mL

5.9287 mL

10 mM

0.2964 mL

1.4822 mL

2.9644 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Iino H, et al. Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles. Biol Pharm Bull. 2015;38(10):1645-8. [Content Brief]

[2]. Hayato Iino, et al. Penetration of Ufenamate into Intact, Stripped, or Delipidized Skin Using Different Vehicles. Bio Pharm Bull. 2015;38(10):1645-8. [Content Brief]

[3]. Ting Lü, et al. Photoprotective effect of butyl flufenamate ointment on SKH-1 hairless mice. Chinese Journal of Dermatology ; (12): 711-715, 2013.

[4]. Fan Yang, et al. Topical Application of Butyl Flufenamate Ointment Promotes Cranial Defect Healing in Mice by Inducing BMP2 Secretion in Skin Mesenchymal Stem Cells. Cells. 2022 Nov 15;11(22):3620. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9644 mL	14.8218 mL	29.6437 mL	74.1092 mL
	5 mM	0.5929 mL	2.9644 mL	5.9287 mL	14.8218 mL
	10 mM	0.2964 mL	1.4822 mL	2.9644 mL	7.4109 mL
	15 mM	0.1976 mL	0.9881 mL	1.9762 mL	4.9406 mL
	20 mM	0.1482 mL	0.7411 mL	1.4822 mL	3.7055 mL
	25 mM	0.1186 mL	0.5929 mL	1.1857 mL	2.9644 mL
	30 mM	0.0988 mL	0.4941 mL	0.9881 mL	2.4703 mL
	40 mM	0.0741 mL	0.3705 mL	0.7411 mL	1.8527 mL
	50 mM	0.0593 mL	0.2964 mL	0.5929 mL	1.4822 mL
	60 mM	0.0494 mL	0.2470 mL	0.4941 mL	1.2352 mL
	80 mM	0.0371 mL	0.1853 mL	0.3705 mL	0.9264 mL
	100 mM	0.0296 mL	0.1482 mL	0.2964 mL	0.7411 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ufenamate

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All COX Isoforms

All Prostaglandin Receptor Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ufenamate

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Osteogenesis Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

All COX Isoforms

All Prostaglandin Receptor Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ufenamate Related Classifications

HY-100009 Related Classifications